福莫司汀治疗未经治疗的不可切除非小细胞肺癌的II期研究。

Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.

作者信息

Rudd R, Allen R, Berille J, Spiro S G, Trask C, Souhami R L

机构信息

London Chest Hospital, UK.

出版信息

Cancer Chemother Pharmacol. 1994;34(5):444-6. doi: 10.1007/BF00685572.

DOI:10.1007/BF00685572

PMID:8070014

Abstract

A total of 43 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a novel nitrosourea, fotemustine, given at 100 mg/m2 on days 1 and 8. Maintenance treatment consisted of a single injection of 100 mg/m2 given every 21 days. 37 patients were evaluable for response. Of these, 5 patients had a partial response (13.5%; 95% confidence interval, 6%-28%). Toxicity comprised mainly anaemia and thrombocytopenia. Other toxicities were mild. This phase II study confirms that fotemustine is a moderately active and well-tolerated drug in NSCLC.

摘要

共有43例晚期、未经治疗的非小细胞肺癌（NSCLC）患者接受了一种新型亚硝基脲——福莫司汀的治疗，第1天和第8天的给药剂量为100mg/m²。维持治疗为每21天单次注射100mg/m²。37例患者可评估疗效。其中，5例患者有部分缓解（13.5%；95%置信区间，6%-28%）。毒性主要包括贫血和血小板减少。其他毒性较轻。这项II期研究证实，福莫司汀在NSCLC中是一种活性中等且耐受性良好的药物。